Tag: Boston Scientific

ELUVIA

Endovascular intervention for the treatment of femoropopliteal lesions: ELUVIA is safe...

This advertorial is sponsored by Boston Scientific. Boston Scientific leads the largest clinical programme investigating drug-eluting therapy for the treatment of peripheral arterial disease (PAD),...

VIVA 2019: Boston Scientific announces positive data for the Ranger DCB...

Boston Scientific today announced positive data for two devices within the peripheral drug-eluting product portfolio during separate late-breaking clinical trial presentations at the 2019...

Michael Jaff joins Boston Scientific to drive innovation in peripheral technologies

Michael R Jaff is to be vice president, clinical affairs, innovation and technology, peripheral interventions of Boston Scientific by January 2020. In this role,...

CIRSE 2019: Hear the latest from clinical trials comparing paclitaxel technologies...

NOTE: ONLY intended for healthcare professionals outside of the USA and France. Zoom in on a tête-à-tete between Marianne Brodmann (Graz, Austria) and Giovanni Torsello...
acquisition

Boston Scientific closes acquisition of BTG

Boston Scientific has announced the completion of its acquisition of BTG, pursuant to the previously announced scheme of arrangement. BTG develops and commercialises products...
Mayo

Boston Scientific signs medical technology alliance with Mayo Clinic

Medical devices manufacturer Boston Scientific has partnered with Mayo Clinic, a non-profit academic medical centre, to launch an accelerator focused on medical solutions for...

Varian Medical acquires two Boston Scientific product lines

Radiation therapy firm Varian Medical Systems has signed an agreement to acquire Boston Scientific's portfolio of drug-loadable microsphere and bland embolic bead products designed...

Only Eluvia Uses a Polymer for Controlled, Targeted Delivery of the...

Eluvia DES is the only technology that uses polymer-based drug delivery to treat Peripheral Artery Disease (PAD). Its polymer ensures that the majority of...

Eluvia drug-eluting stent continues to demonstrate positive outcomes in IMPERIAL trial...

Boston Scientific has announced results from sub-analyses of the IMPERIAL clinical trial for the Eluvia Drug-Eluting Vascular Stent System. Data demonstrated that the efficacy...
vici

Boston Scientific launches new stent for venous obstructive disease

Boston Scientific has won FDA approval for its Vici Venous Stent System for the treatment of iliofemoral venous obstructive disease. The device received CE mark...

Hear the latest thoughts on paclitaxel from global experts: Their current...

 Following the latest information presented at the Charing Cross (CX) International Symposium related to the meta-analysis of paclitaxel-coated devices (Katsanos et al), hear from a...
medtronic

Medtronic and Boston Scientific stand by paclitaxel devices despite Katsanos’ critical...

Speaking to investors at the JP Morgan healthcare conference in San Francisco, executives from Medtronic and Boston Scientific said their data do not show...
acquisition

Boston Scientific announces recommended offer to acquire BTG

Boston Scientific has announced it has reached an agreement on the terms of a recommended offer to acquire BTG, a company headquartered in the...

Positive outcomes for Eluvia stent in long lesion IMPERIAL sub-study

Clinical outcomes from the IMPERIAL Long Lesion Sub-study were presented at VIVA (5–8 November, Las Vegas, USA) demonstrating that the Eluvia drug-eluting vascular stent...

Eluvia outperforms Zilver PTX in IMPERIAL 12-month results

The Eluvia drug-eluting vascular stent system (Boston Scientific) shows superior primary patency compared to the Zilver PTX drug-eluting stent (Cook Medical), concludes the 12-month...
SpaceOAR

Boston Scientific announces agreement to acquire Augmenix

  Boston Scientific has announced that it has entered into a definitive agreement to acquire Augmenix, a privately-held company which has developed and commercialised the...

Boston Scientific announces agreement to acquire Veniti

Boston Scientific has signed an agreement to acquire Veniti, a privately-held company in Fremont, USA which developed and commercialised the Vici venous stent system for...

Explore how to enhance your ability to access challenging treatment sites

This content is for distribution within USA only. The Direxion™ Microcatheter, with its unique shaft design, offers you unrivaled torqueability for improved maneuverability. Further enhancing...

Our guidewire design revolutionizes the ability to access even the most...

This content is for distribution within USA only. As you pursue new and innovative procedures within more complex anatomy, you need precision and control like...

First data from head-to-head comparison of Ranger and IN.PACT drug-coated balloons...

Early data from the first randomised controlled trial to compare two drug-coated balloons (DCBs) suggest that the primary patency obtained with the Ranger DCB...

Eluvia paclitaxel-eluting stent shows long-term freedom from revascularisation at three years

Boston Scientific has announced the three-year results from the MAJESTIC trial for the Eluvia paclitaxel-eluting vascular stent system at the Cardiovascular and Interventional Radiological...